Global Breast Cancer Therapeutics Market Outlook To 2025: Key Treatment Categories (Chemotherapy, Surgery & Radiation therapy, Targeted Therapy and Hormonal Therapy), Drug Class (HER2 Inhibitors Drugs, Mitotic Inhibitors Drugs, Anti-metabolites Drugs, Aromatase Inhibitors Drugs, Hormone Receptor Drugs), Distribution Channel (Hospitals, Drug Store, Specialty Pharmacy, E-Pharmacy), Regional Segmentation, Competitive Dynamics, M&A Insights, Pricing Analysis (OPP, IPP, RAP), And Segment Forecast

$5,650.00$12,650.00

Clear
  • Report Description
  • Table of Content
  • Highlight
  • Research Methodology
  • Request Free Sample

The global breast cancer therapeutics market was valued at $17.4 Billion in 2017 and is forecast to grow at a modest XX.2 % CAGR between 2018 and 2025, culminating in 2025 global sales of $35.5 Billion.

 

As per WHO, 508 000 women worldwide died due to breast cancer in 2011 (Global Health Estimates, WHO 2013) and the trend keep rising. Although it is considered a disease of the developed world, almost 50% of breast cancer cases and 58% of deaths occur in less developed countries (GLOBOCAN 2008). Due to recent development in therapeutic and radiation therapy, survival rates ranging from 80% or over in North America, Sweden, and Japan to around 60% in middle-income countries and below 40% in low-income countries

 

Long exposure to endogenous estrogens, such as early menarche, late menopause, late age at first childbirth is among the most important risk factors for breast cancer. Exogenous hormones, oral contraceptive, and hormone replacement therapy put patients at higher risk for breast cancer. Breastfeeding has a protective effect.

 

Global Breast Cancer Therapeutics Market Outlook To 2025

 

Pricing Analysis

 

“Optimal Price Point (OPP) for Breast Cancer Therapeutic Products”

 

Estimated Average product/ service cost – $ xx globally. However, with improving access and availability of options, OPP and range of acceptable Prices (RAP) are going to change. We at Ameri Research continuously track these prices with our proprietary pricing model.

 

Due to the wide array of products available in the market, pricing, positioning, and sales channel optimization play a vital role in the success of a product. On an average, in the U.S., the breast cancer drugs are available at USD xxx- USD xxxx. However, the high-end products are available at much higher prices. The prices in emerging countries and developed countries vary significantly due to the difference in purchasing power and availability of latest products.

 

 

 

 

Breast Cancer Therapeutics Market by “Treatment Categories”

 

We have segmented the breast cancer treatment market into chemotherapy, surgery & radiation therapy, targeted therapy, and hormonal therapy. Chemotherapy category can be further segmented into antimetabolites, anthracyclines, epothilones, taxanes and alkylating agents. Hormone therapy into aromatase inhibitors and Selective Estrogen-Receptor Modulators (SERMs). Targeted therapy into monoclonal antibodies and tyrosine kinase inhibitors. During our study, we have observed the dominance of chemotherapy followed by surgery & radiation therapy.  Targeted therapy is the fastest growing segment due to superior benefits such as targeted action, minimum damage to surrounding tissue, quick recovery rate, increased efficacy, and less toxic levels.

 

Breast Cancer Therapeutics Market by “Drug Class”

 

Note- Breast Cancer Therapeutic Market by “Drug Class” doesn’t include Chemotherapy, Surgery and Radiation Therapy.

The global breast cancer drug market was valued at $12.4 Billion in 2017 and is forecast to grow at a modest XX.2 % CAGR between 2018 and 2025, culminating in 2025 global sales of $24.2 Billion.

We have broadly segmented the market as HER2 Inhibitors, Mitotic Inhibitors, Anti-metabolites, Aromatase Inhibitors, Hormone Receptor. We have listed leading drugs within those categories in our report. The highest-growing segment in this category is HER2-positive with sales rising from $7.6 billion to $18.5 billion during the forecasting period growing at a CAGR of 8.2%. However, some segments are relatively small in size and growing at a CAGR of 4.8%.

 

Breast Cancer Therapeutics Market by “Distribution Channel”

 

We have segmented the market based on distribution channel as Hospitals, Drug Store, Specialty Pharmacy, E-Pharmacy. Majority of products channelized through hospitals (Particularly Chemo, Surgery and Radiation). However, we are observing the increased role of specialized pharmacy and E-pharmacy in the distribution/ dispensation of treatment drugs. Patient education to increase compliance and Persistency plays a key role in the outcome. Many payors are linking requirement to the outcome.

 

Regional Segmentation

 

North America accounted for the maximum revenue share of over 40% in 2017 due to increased patient number, lifestyle followed by women, late pregnancy, usage of contraceptives, availability of treatment options, better reimbursement plan, and RND.  Followed by EU- Top 5 countries contribute $4.6 Billion in 2017 and expected to reach $6.5 Billion by 2023.

In last 40 years, Breast Cancer treatment market dominated by two drugs – tamoxifen for hormone-positive breast cancer and Roche’s Herceptin (trastuzumab) for the HER2-positive subtype. Herceptin dominance will end soon by launch of biosimilars and new-generation agents.

With changing lifestyle in developing countries and availability of treatment option, we are observing a rise in patient numbers in developing countries. However, these markets represent a minuscule percentage of the overall market.

 

“Competitive Landscape” and “Merger & Acquisition Insights”

 

The key market participants include Novartis International AG, AstraZeneca plc, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Eisai Co. Ltd., GlaxoSmithKline plc, Pfizer Inc., Puma Biotechnology Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd. The growing investment in research and development is driving the companies to innovate, stay market relevant and retain their share. Moreover, there are several startup companies working on stem cell and biologic research, and these companies are considered as strategic assets for merger and acquisition. Some of the most notable transactions in the recent past include,

  • Bayer paying Loxo Oncology $400 million upfront in November 2017 for global rights to larotrectinib and LOXO-195, a second-generation TRK-fusion drug.
  • Roche Holding acquiring Ignyta in a $1.7 billion all-cash deal, exploring origin agnostic approaches to cancer treatment.

 

Market Segmentation

 

Breast Cancer Therapeutics Market by Treatment Categories (Revenue, Million, 2014 – 2025)

  • Chemotherapy
  • Surgery & Radiation therapy
  • Targeted Therapy
  • Hormonal Therapy

Breast Cancer Therapeutics Market by Drug Class (Revenue, Million, 2014 – 2025)

  • HER2 Inhibitors
    • Herceptin (Trastuzumab)
    • Tykerb (Lapatinib)
    • Kadcyla (Ado-trastuzumab emtansine)
    • Perjeta (Pertuzumab)
  • Mitotic Inhibitors
    • Halaven (Eribulin)
    • Taxotere (Docetaxel)
    • Ixempra (Ixabepilone)
  • Anti-metabolites
    • Gemzar (Gemcitabine)
    • Capecitabine (Xeloda®)
  • Aromatase Inhibitors
    • Femara (Leterozole)
    • Aromasin (Exemestane)
    • Arimidex (Anastrozole)
    • Ibrance (Palbociclib)
    • Afinitor (Everolimus)
  • Hormone Receptor
    • Zoladex
    • Faslodex
    • Fareston

Breast Cancer Therapeutics Market by Distribution Channel (Revenue, Million, 2014 – 2025)

  • Hospitals
  • Drug Store
  • Specialty Pharmacy
  • E-Pharmacy

Breast Cancer Therapeutic Market Regional Outlook (Revenue, USD Million, 2014- 2025)

  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
  • Asia Pacific
    • Japan
    • China
    • India
  • Latin America
    • Brazil
    • Mexico
    • Columbia
  • Middle East and Africa
    • South Africa
    • Saudi Arabia

 

 

Breast Cancer Therapeutics Market, Breast Cancer Therapeutics Market Analytics, Breast Cancer Therapeutics Market Share, Breast Cancer Therapeutics Market Research, Breast Cancer Therapeutics Market Forecast, Breast Cancer Therapeutics Market Insight, Breast Cancer Therapeutics Market Trend, Breast Cancer Therapeutics Market Value,Breast Cancer Therapeutics Market Size, Breast Cancer Therapeutics Market Analysis, Breast Cancer Therapeutics Market Survey, Breast Cancer Drugs Market, Breast Cancer Drugs Market Analytics, Breast Cancer Drugs Market Share, Breast Cancer Drugs Market Research, Breast Cancer Drugs Market Forecast, Breast Cancer Drugs Market Insight, Breast Cancer Drugs Market Trend, Breast Cancer Drugs Market Value,Breast Cancer Drugs Market Size, Breast Cancer Drugs Market Analysis, Breast Cancer Drugs Market Survey

Chapter 1 Methodology and Scope

  • Research Methodology
  • Research Scope & Assumptions
  • List of Data Sources

Chapter 2 Executive Summary

Chapter 3 Breast Cancer Therapeutics Market Overview

  • Global Disease Landscape
  • Global Healthcare Expenditure

Chapter 4 Breast Cancer Therapeutics Industry Outlook

  • Market Overview
  • Market Segmentation
  • Market Size and Growth Prospects
  • Leading Brand Dynamics
  • Key Market Drivers
    • Higher Incidence Rate
    • Increased diagnosis and early detection
    • Increasing R&D Investment
    • Better reimbursement plans
    • Technological Advancements and newer drug approval
  • Key Market Challenges
    • Access barrier to high cost drugs
    • Serious side effect to Breast Cancer Drugs
    • Lack of Awareness and reimbursement plans in Emerging Countries
  • Key Opportunities Prioritized
  • Industry Analysis - Porter’s
  • Breast Cancer Therapeutics Market-PESTEL Analysis

Chapter 5: - Breast Cancer Therapeutics Market by “Treatment Categories” (USD Million)

  • Breast Cancer Therapeutics Market Landscape by Treatment Categories- 2017 & 2025
    • Chemotherapy
  • Market Landscape Analysis, 2017-2025
    • Surgery & Radiation therapy
  • Market Landscape Analysis, 2017-2025
    • Targeted Therapy
  • Market Landscape Analysis, 2017-2025
    • Hormone Therapy
  • Market Landscape Analysis, 2017-2025

Chapter 6: - Breast Cancer Therapeutics Market by “Drug Class” (USD Million)

  • Breast Cancer Therapeutics Market Landscape by Drug Class- 2017 & 2025
    • HER2 Inhibitors
      • Market Landscape Analysis, 2017-2025
    • Mitotic Inhibitors
      • Market Landscape Analysis, 2017-2025
    • Anti-metabolites
      • Market Landscape Analysis, 2017-2025
    • Aromatase Inhibitors
      • Market Landscape Analysis, 2017-2025
    • Hormone Receptor
      • Market Landscape Analysis, 2017-2025

Chapter 7: - Breast Cancer Therapeutics Market by “Distribution Channel” (USD Million)

  • Breast Cancer Therapeutics Market Landscape by Distribution Channel- 2017 & 2025
    • Hospitals
      • Market Landscape Analysis, 2017-2025
    • Drug Store
      • Market Landscape Analysis, 2017-2025
    • Specialty Pharmacy
      • Market Landscape Analysis, 2017-2025
    • E-Pharmacy
      • Market Landscape Analysis, 2017-2025

Chapter 10: Regional Market Outlook

Breast Cancer Therapeutics Market Landscape by Region- 2017
  • North America Market Landscape Analysis, 2017-2025 (USD Mn)
    • U.S. Market Landscape Analysis, 2017-2025
    • Canada Market Landscape Analysis-2017-2025
  • Europe Market Landscape Analysis, 2017-2025 (USD Mn)
    • UK Market Landscape Analysis, 2017-2025
    • Germany Market Landscape Analysis, 2017-2025
    • France Market Landscape Analysis, 2017-2025
    • Italy Market Landscape Analysis, 2017-2025
    • Spain Market Landscape Analysis, 2017-2025
  • Latin America Market Landscape Analysis, 2017-2025 (USD Mn)
    • Brazil Market Landscape Analysis, 2017-2025
    • Mexico Market Landscape Analysis, 2017-2025
    • Colombia Market Landscape Analysis, 2017-2025
  • Asia pacific Market Landscape Analysis, 2017-2025 (USD Mn)
    • Japan Market Landscape Analysis, 2017-2025
    • China Market Landscape Analysis, 2017-2025
    • India Market Landscape Analysis, 2017-2025
    • Australia Market Landscape Analysis, 2017-2025
    • Korea Market Landscape Analysis, 2017-2025
  • Middle East & Africa Market Landscape Analysis, 2014-2025 (USD Mn)
    • Saudi Arabia Market Landscape Analysis, 2014-2025
    • South Africa Market Landscape Analysis, 2014-2025
 

Chapter 11: Pricing Analysis

 
  • Optimal Price Points (OPP), Indifference price points (IPP) and Range of Acceptable Prices and (RAP) of leading brands by Region- 2017
  • North America Pricing Analysis (OPP, IPP, and RAP - 2017)
    • U.S. Pricing Analysis-2017
    • Canada Pricing Analysis-2017
  • Europe Pricing Analysis (OPP, IPP, and RAP - 2017)
    • UK Pricing Analysis-2017
    • Germany Pricing Analysis-2017
    • France Pricing Analysis-2017
    • Italy Pricing Analysis-2017
    • Spain Pricing Analysis-2017
  • Latin America Pricing Analysis (OPP, IPP, and RAP - 2017)
    • Brazil Pricing Analysis-2017
    • Mexico Pricing Analysis-2017
    • Colombia Pricing Analysis-2017
  • Asia Pacific Pricing Analysis (OPP, IPP, and RAP - 2017)
    • Japan Pricing Analysis-2017
    • China Pricing Analysis-2017
    • India Pricing Analysis-2017
  • Middle East Pricing Analysis (OPP, IPP, and RAP - 2017)
    • Saudi Arabia Pricing Analysis-2017
    • South Africa Pricing Analysis-2017

Chapter 12: Breast Cancer Therapeutics Pipeline Analysis

  • Executive Summary
  • Late Stage Pipeline analysis
  • Key R&D trends

Chapter 13: Breast Cancer Therapeutics Merger & Acquisition Outlook

  • Factors driving M&A in Breast Cancer Therapeutics market
  • Key trends and future outlook

Chapter 14: Competitive Landscape

  • Novartis International AG
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • AstraZeneca plc
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Hoffmann-La Roche Ltd
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Eli Lilly
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Eisai Co. Ltd.,
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • GlaxoSmithKline
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Pfizer Inc
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Puma Biotechnology Inc.,
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Sanofi
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Teva Pharmaceutical
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
   

List of Tables

 
  • TABLE 1 Breast Cancer Therapeutics Market - Industry Snapshot & Key Buying Criteria, 2014 - 2025
  • TABLE 2 Global Breast Cancer Therapeutics Market, 2014 – 2025
  • TABLE 3 Global Breast Cancer Therapeutics Market Analysis by Product-2017
  • TABLE 4 Global Breast Cancer Therapeutics Market Analysis by Technology -2017
  • TABLE 5 Global Breast Cancer Therapeutics Market Analysis by Application-2017
  • TABLE 7 Global Breast Cancer Therapeutics Market Analysis by Geography-2017
  • TABLE 8 Global Breast Cancer Therapeutics Market Analysis by Leading Brands-2017
  • TABLE 9 Breast Cancer Therapeutics Market - Key market driver analysis
  • TABLE 10 Breast Cancer Therapeutics Market - Key market restraint analysis
  • TABLE 11 North America Market Breast Cancer Therapeutics Landscape Analysis, 2017-2025 (USD Mn)
  • TABLE 12U.S. Breast Cancer Therapeutics Market Landscape Analysis, 2017-2025
  • TABLE 13 Canada Breast Cancer Therapeutics Market Landscape Analysis, 2017-2025
  • TABLE 14 Europe Breast Cancer Therapeutics Market Landscape Analysis, 2017-2025 (USD Mn)
  • TABLE 15 U.K Breast Cancer Therapeutics Market Landscape Analysis, 2017-2025
  • TABLE 16 Germany Breast Cancer Therapeutics Market Landscape Analysis, 2017-2025
  • TABLE 17 France Breast Cancer Therapeutics Market Landscape Analysis, 2017-2025
  • TABLE 18 Italy Breast Cancer Therapeutics Market Landscape Analysis, 2017-2025
  • TABLE 19 Spain Breast Cancer Therapeutics Market Landscape Analysis, 2017-2025
  • TABLE 20 Latin America Breast Cancer Therapeutics Market Landscape Analysis, 2017-2025 (USD Mn)
  • TABLE 21 Brazil Breast Cancer Therapeutics Market Landscape Analysis, 2017-2025
  • TABLE 22 Mexico Breast Cancer Therapeutics Market Landscape Analysis, 2017-2025
  • TABLE 20 Colombia Breast Cancer Therapeutics Market Landscape Analysis, 2017-2025
  • TABLE 21 Asia pacific Breast Cancer Therapeutics Market Landscape Analysis, 2017-2025 (USD Mn)
  • TABLE 22 Japan Breast Cancer Therapeutics Market Landscape Analysis, 2017-2025
  • TABLE 23 China Breast Cancer Therapeutics Market Landscape Analysis, 2017-2025
  • TABLE 24 India Breast Cancer Therapeutics Market Landscape Analysis, 2017-2025
  • TABLE 25 North America Pricing Analysis
  • TABLE 26 North America Pricing Analysis (OPP, IPP, and RAP- 2017)
  • TABLE 27 U.S. Pricing Analysis-2017
  • TABLE 28 Canada Pricing Analysis-2017
  • TABLE 29 Europe Pricing Analysis (OPP, IPP, and RAP- 2017)
  • TABLE 30 U.K Pricing Analysis-2017
  • TABLE 31 Germany Pricing Analysis-2017
  • TABLE 32 France Pricing Analysis-2017
  • TABLE 33 Italy Pricing Analysis-2017
  • TABLE 34 Spain Pricing Analysis-2017
  • TABLE 35 Latin America Pricing Analysis (OPP, IPP, and RAP- 2017)
  • TABLE 36 Brazil Pricing Analysis-2017
  • TABLE 37 Mexico Pricing Analysis-2017
  • TABLE 38 Colombia Pricing Analysis-2017
  • TABLE 39 Asia Pacific Pricing Analysis (OPP, IPP, and RAP- 2017)
  • TABLE 40 Japan Pricing Analysis-2017
  • TABLE 41 China Pricing Analysis-2017
  • TABLE 42 India Pricing Analysis-2017
  • TABLE 43 Middle East Pricing Analysis (OPP, IPP, and RAP- 2017)
  • TABLE 44 Saudi Arabia Pricing Analysis-2017
  • TABLE 45 South Africa Pricing Analysis-2017
 

List of Figures

 
  • 1 Breast Cancer Therapeutics Market Segmentation
  • 2 Market Size & Growth Prospects
  • 3 Leading Brand Dynamics
  • 4 Penetration & Growth Prospects
  • 5 Industry Analysis – Porter’s
  • 6 Breast Cancer Therapeutics Market – PESTEL Analysis
  • 7 Breast Cancer Therapeutics Market Share by Product Type, 2017 & 2025
  • 7 Breast Cancer Therapeutics Market Share by Cell Type, 2017 & 2025
  • 7 Breast Cancer Therapeutics Market Share by Technique, 2017 & 2025
  • 7 Breast Cancer Therapeutics Market Share by Application, 2017 & 2025
  • 7 Breast Cancer Therapeutics Market Share by End-Use, 2017 & 2025
  • 10 Breast Cancer Therapeutics Market Share by Region, 2017 & 2025

Key Insights Addressed:  

  • Defining market size from 2014 to 2017.
  • Estimating market growth till 2025 and consequence market forecast.
  • Identifying market drivers, restraints & future opportunities and allowing decision-maker with a range of possible outcomes and the probabilities that will occur for any choice of action.
  • Market segments and regions that will drive or lead market growth.
  • Defining Optimal Price Point (OPP) which will be accepted and recommended by maximum customers.
  • A bird’s-eye view of competitive landscape and the key market players.
  • Key strategic growth driver adopted by market players. In-depth analysis of their strategies and implication on competition & growth.
    Key Findings:  
  • The global breast cancer therapeutics market was valued at $17.4 Billion in 2017 and is forecast to grow at a modest XX.2 % CAGR between 2018 and 2025, culminating in 2025 global sales of $35.5 Billion.
  • As per WHO, 508 000 women worldwide died due to breast cancer in 2011 (Global Health Estimates, WHO 2013) and the trend keep rising.
  • We have segmented the breast cancer treatment market into chemotherapy, surgery & radiation therapy, targeted therapy and hormonal therapy.
  • The global breast cancer drug market was valued at $12.4 Billion in 2017 and is forecast to grow at a modest XX.2 % CAGR between 2018 and 2025, culminating in 2025 global sales of $24.2 Billion.
  • The key market participants include Novartis International AG, AstraZeneca plc, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Eisai Co. Ltd., GlaxoSmithKline plc, Pfizer Inc., Puma Biotechnology Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd.

Ameri Research implies a unique methodology of published information and primary research to bring key insights to customer decision making process. Our analytics model helps us to understand the structured and unstructured information from various sources. Key steps involves in the process are as below-

    1. Analyzing Published Information- Access to large pool of paid and unpaid published information via different sources and analyzing market trend.
    2. Setting Foundation- Input from analysis of secondary sources set our foundation to market analysis and helps in setting the scope for further research. Setting the scope involves Ameri Research proprietary statistical model, discussion with industry leaders, internal brainstorming, key discussion pointers from various forums etc.
    3. Need Gap Analysis- Defining the gap between our scope and availability of information.
    4. KOL Panel Discussion- Focused Group Discussion with a structured discussion guide to fine tune the gap and deriving the factors driving/restraining the market trend.
    5. Quantitative Research- Sampling large number of industry players, Education/Research Institutes, Government bodies, NGOs, Individual acclaimed researchers and conducting the primary interview with a structured questionnaire.
    6. Data Triangulation- We apply bottom-up demand approach or top-down estimation or a combined approach to triangulate the data points.
    7. Analyst Comment- Each of our analysts carries large pool of experience from domain perspective and add their value which is directional in nature
global-aesthetic-dermatology-market

To request a free sample copy of this report, please complete the form below verified and secure

We offer complete free customization that addresses client’s need. This includes insights from primary market research and a 60-minute free analyst consultation post report purchase.

This website is secure and your personal details are safe. Privacy policy

Description

The global breast cancer therapeutics market was valued at $17.4 Billion in 2017 and is forecast to grow at a modest XX.2 % CAGR between 2018 and 2025, culminating in 2025 global sales of $35.5 Billion.

 

As per WHO, 508 000 women worldwide died due to breast cancer in 2011 (Global Health Estimates, WHO 2013) and the trend keep rising. Although it is considered a disease of the developed world, almost 50% of breast cancer cases and 58% of deaths occur in less developed countries (GLOBOCAN 2008). Due to recent development in therapeutic and radiation therapy, survival rates ranging from 80% or over in North America, Sweden, and Japan to around 60% in middle-income countries and below 40% in low-income countries

 

Long exposure to endogenous estrogens, such as early menarche, late menopause, late age at first childbirth is among the most important risk factors for breast cancer. Exogenous hormones, oral contraceptive, and hormone replacement therapy put patients at higher risk for breast cancer. Breastfeeding has a protective effect.

 

Global Breast Cancer Therapeutics Market Outlook To 2025

 

Pricing Analysis

 

“Optimal Price Point (OPP) for Breast Cancer Therapeutic Products”

 

Estimated Average product/ service cost – $ xx globally. However, with improving access and availability of options, OPP and range of acceptable Prices (RAP) are going to change. We at Ameri Research continuously track these prices with our proprietary pricing model.

 

Due to the wide array of products available in the market, pricing, positioning, and sales channel optimization play a vital role in the success of a product. On an average, in the U.S., the breast cancer drugs are available at USD xxx- USD xxxx. However, the high-end products are available at much higher prices. The prices in emerging countries and developed countries vary significantly due to the difference in purchasing power and availability of latest products.

 

 

 

 

Breast Cancer Therapeutics Market by “Treatment Categories”

 

We have segmented the breast cancer treatment market into chemotherapy, surgery & radiation therapy, targeted therapy, and hormonal therapy. Chemotherapy category can be further segmented into antimetabolites, anthracyclines, epothilones, taxanes and alkylating agents. Hormone therapy into aromatase inhibitors and Selective Estrogen-Receptor Modulators (SERMs). Targeted therapy into monoclonal antibodies and tyrosine kinase inhibitors. During our study, we have observed the dominance of chemotherapy followed by surgery & radiation therapy.  Targeted therapy is the fastest growing segment due to superior benefits such as targeted action, minimum damage to surrounding tissue, quick recovery rate, increased efficacy, and less toxic levels.

 

Breast Cancer Therapeutics Market by “Drug Class”

 

Note- Breast Cancer Therapeutic Market by “Drug Class” doesn’t include Chemotherapy, Surgery and Radiation Therapy.

The global breast cancer drug market was valued at $12.4 Billion in 2017 and is forecast to grow at a modest XX.2 % CAGR between 2018 and 2025, culminating in 2025 global sales of $24.2 Billion.

We have broadly segmented the market as HER2 Inhibitors, Mitotic Inhibitors, Anti-metabolites, Aromatase Inhibitors, Hormone Receptor. We have listed leading drugs within those categories in our report. The highest-growing segment in this category is HER2-positive with sales rising from $7.6 billion to $18.5 billion during the forecasting period growing at a CAGR of 8.2%. However, some segments are relatively small in size and growing at a CAGR of 4.8%.

 

Breast Cancer Therapeutics Market by “Distribution Channel”

 

We have segmented the market based on distribution channel as Hospitals, Drug Store, Specialty Pharmacy, E-Pharmacy. Majority of products channelized through hospitals (Particularly Chemo, Surgery and Radiation). However, we are observing the increased role of specialized pharmacy and E-pharmacy in the distribution/ dispensation of treatment drugs. Patient education to increase compliance and Persistency plays a key role in the outcome. Many payors are linking requirement to the outcome.

 

Regional Segmentation

 

North America accounted for the maximum revenue share of over 40% in 2017 due to increased patient number, lifestyle followed by women, late pregnancy, usage of contraceptives, availability of treatment options, better reimbursement plan, and RND.  Followed by EU- Top 5 countries contribute $4.6 Billion in 2017 and expected to reach $6.5 Billion by 2023.

In last 40 years, Breast Cancer treatment market dominated by two drugs – tamoxifen for hormone-positive breast cancer and Roche’s Herceptin (trastuzumab) for the HER2-positive subtype. Herceptin dominance will end soon by launch of biosimilars and new-generation agents.

With changing lifestyle in developing countries and availability of treatment option, we are observing a rise in patient numbers in developing countries. However, these markets represent a minuscule percentage of the overall market.

 

“Competitive Landscape” and “Merger & Acquisition Insights”

 

The key market participants include Novartis International AG, AstraZeneca plc, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Eisai Co. Ltd., GlaxoSmithKline plc, Pfizer Inc., Puma Biotechnology Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd. The growing investment in research and development is driving the companies to innovate, stay market relevant and retain their share. Moreover, there are several startup companies working on stem cell and biologic research, and these companies are considered as strategic assets for merger and acquisition. Some of the most notable transactions in the recent past include,

  • Bayer paying Loxo Oncology $400 million upfront in November 2017 for global rights to larotrectinib and LOXO-195, a second-generation TRK-fusion drug.
  • Roche Holding acquiring Ignyta in a $1.7 billion all-cash deal, exploring origin agnostic approaches to cancer treatment.

 

Market Segmentation

 

Breast Cancer Therapeutics Market by Treatment Categories (Revenue, Million, 2014 – 2025)

  • Chemotherapy
  • Surgery & Radiation therapy
  • Targeted Therapy
  • Hormonal Therapy

Breast Cancer Therapeutics Market by Drug Class (Revenue, Million, 2014 – 2025)

  • HER2 Inhibitors
    • Herceptin (Trastuzumab)
    • Tykerb (Lapatinib)
    • Kadcyla (Ado-trastuzumab emtansine)
    • Perjeta (Pertuzumab)
  • Mitotic Inhibitors
    • Halaven (Eribulin)
    • Taxotere (Docetaxel)
    • Ixempra (Ixabepilone)
  • Anti-metabolites
    • Gemzar (Gemcitabine)
    • Capecitabine (Xeloda®)
  • Aromatase Inhibitors
    • Femara (Leterozole)
    • Aromasin (Exemestane)
    • Arimidex (Anastrozole)
    • Ibrance (Palbociclib)
    • Afinitor (Everolimus)
  • Hormone Receptor
    • Zoladex
    • Faslodex
    • Fareston

Breast Cancer Therapeutics Market by Distribution Channel (Revenue, Million, 2014 – 2025)

  • Hospitals
  • Drug Store
  • Specialty Pharmacy
  • E-Pharmacy

Breast Cancer Therapeutic Market Regional Outlook (Revenue, USD Million, 2014- 2025)

  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
  • Asia Pacific
    • Japan
    • China
    • India
  • Latin America
    • Brazil
    • Mexico
    • Columbia
  • Middle East and Africa
    • South Africa
    • Saudi Arabia

 

 

Breast Cancer Therapeutics Market, Breast Cancer Therapeutics Market Analytics, Breast Cancer Therapeutics Market Share, Breast Cancer Therapeutics Market Research, Breast Cancer Therapeutics Market Forecast, Breast Cancer Therapeutics Market Insight, Breast Cancer Therapeutics Market Trend, Breast Cancer Therapeutics Market Value,Breast Cancer Therapeutics Market Size, Breast Cancer Therapeutics Market Analysis, Breast Cancer Therapeutics Market Survey, Breast Cancer Drugs Market, Breast Cancer Drugs Market Analytics, Breast Cancer Drugs Market Share, Breast Cancer Drugs Market Research, Breast Cancer Drugs Market Forecast, Breast Cancer Drugs Market Insight, Breast Cancer Drugs Market Trend, Breast Cancer Drugs Market Value,Breast Cancer Drugs Market Size, Breast Cancer Drugs Market Analysis, Breast Cancer Drugs Market Survey

Additional information

Price

Single User $5,650, Multiple User $8,650, Enterprise User $12,650